Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis
Status:
Enrolling by invitation
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to determine the optimal dose of HL237 tablets in
rheumatoid arthritis patients by comparing the efficacy and safety of the three dose groups
of HL237 tablets and the control group.